A fresh article on the Nature website:
# New schizophrenia drug could treat Alzheimer’s disease
A quote:
Pharmaceutical giant Bristol Meyers Squibb (BMS), based in New York, which acquired Karuna in March, is running a trial in people to test whether KarXT can also help to treat psychosis associated with Alzheimer’s disease, as well as investigating whether the drug might benefit people with bipolar disorder.
Given the role of M1 receptors in cognition, researchers are also designing drugs that target that receptor to reduce cognitive decline in people with Alzheimer’s disease. Tobin says researchers are hopeful that muscarinic drugs might also slow its progression. In 2016, he and his colleagues reported that an M1-specific drug slowed neurodegeneration in mice with a disease resembling Alzheimer’s in humans2.